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Summary 
RMA/S is a mutant cell line with decreased cell surface expression of major histocompatibility 
complex class I molecules that has been reported to be deficient in presenting endogenously 
synthesized influenza virus nucleoprotein (NP) to cytotoxic T lymphocytes (CTL). In the present 
study we show that RMA/S cells can present vesicular stomatitis virus nudeocapsid protein, 
and, under some conditions, NP, to K b- and Db-restricted CTL, respectively.  Antigen presenta- 
tion results from processing of cytosolic pools of endogenously synthesized proteins,  and not 
the binding to cell surface class I molecules of antigenic peptides present in the virus inoculum 
or released from infected cells. Antigen processing of RMA/S differs, however, from processing 
by wild-type cells in requiring greater amounts of antigen, longer times to assemble or transport 
class I-peptide complexes, and in being more sensitive to blocking by anti-CD8 antibody. Thus, 
the antigen processing deficit in RMA/S cells is of a partial rather than absolute nature. 
M 
utant cells deficient in the presentation of endogenously 
synthesized antigens have become important tools for 
studying antigen processing: the process by which cells de- 
rive peptides from cytosolic proteins and deliver them across 
an internal membrane to MHC class I molecules. RMA/S 
cells were the first mutant cells appreciated to be deficient 
in  antigen  processing.  Townsend et  al.  (1)  reported  that 
RMA/S cells failed to present influenza virus nucleoprotein 
(NP) 1 to H-2Db-restricted, NP-specific CTL. RMA/S cells 
were originally selected from mutagenized RMA cells on the 
basis of low cell surface expression of class I molecules (2). 
The cells synthesize class I ce chains and flz-microglobulin 
at normal levels, but fail to efftdently assemble these compo- 
nents, resulting in the slow transit of class I molecules to 
the cell surface (1, 3). The stability of class I molecules can 
be enhanced in detergent extracts or at the surface of viable 
RMA/S cells by the addition of antigenic peptides able to 
bind to class I molecules (1, 4). Based on these findings, it 
was suggested that RMA/S cells are deficient either in the 
production of antigenic peptides from proteins,  the trans- 
port of antigen from the cytosol, or in a factor required for 
determinants to efficiently associate with class I molecules 
(1).  In the present study we have further characterized the 
capacity of RMA/S cells to present cytosolic viral antigens 
to CTL. 
t Abbreviations used in  this paper: BFA, brefeldin A; G, glycoprotein; 
N, nucleocapsid;  NP, nucleoprotein;  N-Vac, nudeocapsid/vaccinia  virus 
recombinant; Vac, vaccinia  virus; VSV, vesicuhr stomatitis virus. 
Materials and Methods 
Mice.  6-8-wk-old C57BL/6 (H-2b), CBA/J (H-2k), B10.HTG 
(H-2s), and B10.D2(K107) (H-2  i7) mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). 
Viruses and Peptides.  A/PK/8/34 (HIN1) (PK8) influenza virus 
was used as infectious allantoic fluid. The Indiana strain of vesic- 
ular stomatitis virus (VSV) was grown in BHK-21 cells and used 
as infectious tissue culture supernatants. The infectivity of VSV 
stocks was determined by phquing on BHK-21 cells. The construc- 
tion and characterization ofvaccinia virus (Vac) recombinant con- 
taining the Indiana VSV nucleocapsid (N) gene (N-Vac) has been 
described elsewhere (8). A  peptide  corresponding  to  residues 
365-380 of the PK8 NP (NP36s-~) was synthesized by the Bio- 
logical Resources Branch (NIAID). This peptide is recognized by 
NP-spedfic CTL in conjunction with D b (5). The peptide corre- 
sponding to residues 52-59  of the VSV N  protein  (Ns2-s9)  was 
kindly provided by Dr. Stanley Nathenson  (Albert Einstein Col- 
lege of Medicine, Bronx,  NY).  This  peptide is recognized by 
N-specific CTL in conjunction  with K  b (6). 
Generation of  CTL.  CTL from virus-primed  animals were gener- 
ated from sphnocytes by in vitro stimulation with virus-infected 
autologous splenocytes as described (7, 8), or by adding antigenic 
peptides to the culture medium at a concentration of 1/~g/ml. In 
some instances, cultures were harvested after a 7-d incubation, 
washed, and cultured in fresh medium supplemented with 10% 
(vol/vol) of Con A-stimulated rat spleen cell supernatant for a fur- 
ther 3-5 d. CTL done 33 specific for the N protein of VSV (9) 
was kindly provided by Dr. James Sheil (West Virginia University, 
Morgantown, WV). 
Preparation of Target Cells.  Before  infection with PR8, cells were 
washed twice with PBS and suspended at 107 cells/ml in Autopow 
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20 mM Hepes (pH 7.0) and 0.1% (wt/vol) BSA. 1 ml of PR8 in 
allantoic fluid (2,000 HAU/ml) was added, and cells incubated for 
1 h at 37~  while constantly rotated. 9 ml of IMDM was added 
and cells incubated for further 1-3 h. Cells were then pelleted and 
resuspended in 50-100/A of IMDM containing 100/zCi NaSlCrO4 
(SXCr) and incubated for 1 h at 37~  After washing twice with 
5 ml ice-cold PBS, cells were resuspended in IMDM and used as 
target cells for microcytotoxicity assays. For VSV infection, cells  Exp. 
were resuspended at  107 cells/ml in balanced  salt  solution con- 
taining 0.1% BSA. VSV was added to cells at a multiplicity of 1 
PFU/cell unless otherwise stated. Cells were incubated for 1-2 h 
at 37~  and labeled with SlCr as described above. Alternatively,  A 
target cells were infected with influenza or VSV and SlCr labeled 
at the same time for 1.5 h before plating. Target cells were senti- 
tized with antigenic peptides either during SlCr labeling, or by in-  B 
cluding peptides in the microcytotoxicity assay. Cells were treated 
with brefeldin A (BFA) at a concentration of 5/zg/ml during in- 
fection or peptide labeling and at 2/~g/ml during the cytotoxicity 
assay. The protein synthesis  inhibitor cycloheximide was used at  A 
30/~g/ml throughout the preparation of target cells and the cyto- 
toxicity assay. 
Cytotoxicity Assays.  4-h microcytotoxicity  assays were performed  B 
as previously described (7, 8). Data are expressed as percent specific 
release  defined  as:  100x  [(experimental  cpm  -  spontaneous 
cpm)/(total  cpm  -  spontaneous  cpm)].  In  all  experiments 
presented, the spontaneous release of target cells was <25% of total 
release values unless  otherwise stated. 
Results 
VSV-infected RMA/S  Cells  Are  Lysed  by  N-specific, g b- 
restricted CTLs.  To gauge the extent of the antigen processing 
deficit of RMA/S cells, we tested their ability to present VSV 
antigens to VSV-specific CTL.  VSV was chosen since pre- 
liminary experiments indicated that RMA/S,  while highly 
resistant to infection with vacdnia virus, and somewhat resis- 
tant to influenza virus, were highly susceptible to VSV infec- 
tion. To our surprise, VSV-infected RMA/S cells were lysed 
at similar levels to VSV-infected RMA cells (Table 1). Rec- 
ognition was antigen specific since PR8 NP-specitic CTL lysed 
VSV-infected cells at only background levels and vice versa. 
The identity of RMA/S cells is confirmed by their failure 
to present hiP after infection with PR8 in the same experiment. 
Based on the findings of Van Bleek and Nathenson (6), 
we suspected that CTL recognition of VSV-infected RMA/S 
cells was predominantly, if not entirely, based on presenta- 
tion of residues Ns2-s9 in association with K b (6).  Indeed, 
N-specific CTL induced by VSV stimulation of splenocytes 
from mice primed with N-Vac (8) lysed VSV-infected RMA/S 
cells at comparable levels to VSV-infected RMA cells (Table 2). 
Similar results were obtained using splenocytes from B10.D2 
(R107) mice (KbDd), while splenocytes from B10.HTG mice 
(KdD b) failed to lyse VSV-infected RMA or RMA/S cells, 
demonstrating that N  was presented exclusively in associa- 
tion with K b (Table 2). Further, CTL induced by stimulat- 
ing splenocytes from VSV-primed animals with a synthetic 
pepfide corresponding to the Nsz-s9 sequence efficiently lysed 
VSV-infected RMA/S cells (Table 2), and a CTL clone previ- 
ously shown to recognize Ns2-s9 determinant in association 
Table  1.  Presentation of Influenza Virus and VSV Antigens 
to CTL after Infection of RMA and RMA/S  Cells 
Cells  Virus  Time 
Percent specific 
SXCr release 
Anti-NP  Anti-VSV 
1  2  3  4 
RMA 
RMA/S 
PR8  90'  54  36  2  3 
VSV  90'  16  21  66  73 
PR8  90'  57  51  0 
PR8  180'  83  81  0 
PR8  90'  3  3  4  5 
VSV  90'  21  14  70  69 
PR8  90'  0  0  0 
PR8  180'  20  16  0 
VSV  90'  0  0  53 
Cells were infected with PR8 or VSV for 90 or 180 min before testing 
in a 4-h cytotoxicity assay. Anti-NP and anti-VSV CTL were generated 
from spleen cells derived from mice infected with influenza  virus or VSV 
and stimulated in vitro with NP56s-3s0 and VSV, respectively. Effector 
cells were incubated with target cells in Exp. A at ratios of 20:1 (1 and 
3) or 10:1 (2 and 4), and in Exp. B at 40:1 (I) or 20:1 (2 and 3). Back- 
ground values obtained using the same populations with uninfected cells 
have been subtracted from all values. These ranged from 1% to 12%. 
with  K b (6)  also  efficiently recognized RMA/S  cells (Ta- 
ble 2). 
RMA/S Cells Present Endogenously SFatkesized N Protein.  It 
was essential to demonstrate that recognition of RMA/S cells 
by N-specific CTL was based on presentation of endogenously 
synthesized N,  and not antigenic peptides either present in 
the virus inoculum or released by infected cells during the 
assay.  This was demonstrated  in three ways. 
First,  we blocked viral gene expression by adding a pro- 
tein synthesis inhibitor at the time of infection and main- 
taining the blockade throughout  the preparation  of target 
ceils and the SlCr release assay. This completely blocked pre- 
sentation of VSV antigens  (Table 3). Second, we examined 
the effect of BFA on the ability of VSV-infected RMA/S cells 
to present N  protein to CTL. BFA is known to prevent pre- 
sentation of endogenously synthesized antigens,  while not 
affecting presentation of exogenously provided peptides (10, 
11).  BFA completely inhibited  presentation  of N  by VSV- 
infected ceils (Table 3). As observed previously, this represents 
a specific effect on the presentation of endogenously synthe- 
sized  antigens,  since  BFA  did  not  affect  presentation  of 
Ns2-sg.  Furthermore,  the effect of BFA on presentation  of 
N  cannot be attributed  to a blockade of virus penetration 
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Percent  specific SlCr release 
C57BL/6  C57BL/6  B10.HTG  B10.D2  (R107) 
(KbD  b)  (KbD  b)  (KaD  b)  (KbO  d) 
N-VAC  1 ~  N-VAC  1 ~  N-VAC  1  ~  N-VAC  1 ~ 
VSV 2 ~  Ns2-s9 2 ~  VSV  2 ~  VSV  2 ~  CLONE 33 
Cells  Virus  20:1  10:1  20:1  10:1  20:1  10:1  20:1  10:1  1:1  0.5:1 
RMA  None  5  0  0  0  4  2  0  0  0  0 
VSV  77  73  55  49  11  3  72  74  67  61 
RMA/S  None  0  0  0  0  0  0  0  0  0  0 
VSV  68  56  38  22  0  0  70  61  50  48 
Target cells were infected with VSV for 2 h and tested in a 4-h cytotoxicity assay. N-specific CTL were derived from mouse strains with the designat- 
ed MHC haplotypes by either priming mice with N-Vac and restimulating in vitro with VSV, or with Nsz-s9 and were used at an E/T ratio of 
20:1 or 10:1. Clone 33 is a Kb-restricted CTL clone specific for Ns2-sg, and was used at E/T ratios of 1:1 and 0.5:1. 
Table  3.  Presentation  of N  Can Be Blocked by Cycloheximide 
or BFA 
Percent  specific 
SICr release 
RMA  RMA/S 
Exp.  Treatment  20:1  10:1  20:1  10:1 
A 
B 
None  0  0  0  0 
VSV  64  59  56  47 
VSV  +  r  14  11  1  4 
None  0  0  0  0 
VSV  88  85  64  59 
VSV  +  BFA  0  1  2  4 
VSV  +  BFA  ~  reversed  59  52  39  29 
VSV  +  ￿9  in  assay  56  43  57  46 
VSV  +  BFA  ~  reversed 
+  ￿9  in assay  49  31  31  19 
Ns2-s9  70  60  61  56 
Nsvs9  +  BFA  69  62  57  46 
Cells were infected with VSV or treated with Ns2-s9 at 5  x  10 -6 M 
for 2 h and tested in a cytotoxicity assay. Anti-VSV CTL were generat- 
ed from VSV-primed mice by in vitro stimulation with VSV and were 
used at E/T ratios of 20:1 or 10:1. Cycloheximide (~) was added at 
the beginning of the infection in Exp. A, or at the beginning  of the 
cytotoxicity assay in Exp. B. In Exp. B, BFA was added 15 min after 
VSV or peptide was added to cells, and was maintained throughout  the 
remaining pre-assay  incubation and the cytotoxicity assay. The BFA block- 
ade was reversed by washing the cells before the cytotoxicity  assay. 
or protein synthesis since VSV-infected cells presented N  after 
BFA was removed and cells were incubated with protein syn- 
thesis inhibitors to block any new synthesis of viral proteins 
(Table 3). Third, unlabeled VSV-infccted cells were incubated 
with S*Cr-labeled uninfected cells during a 6-h cytotoxicity 
assay (not  shown).  Although  this  resulted  in  sensitization 
of a  significant  fraction of cells  (39%)  for CTL lysis,  this 
effect was completely blocked by addition  of either protein 
synthesis inhibitors  or BFA to the mixture of cells.  In the 
same experiment,  these inhibitors  did not  block sensitiza- 
tion by exogenous  peptide.  Additionally,  sensitization  was 
almost completely blocked by incubation with a mAb specific 
for VSV glycoprotein (G) with virus neutralizing  activity, 
while a  control  mAb had  little  effect.  Thus,  the observed 
sensitization can be attributed to the release of infectious virions 
from RMA/S cells, and not the release of antigenic peptides 
in sufficient quantity to sensitize target cells for CTL lysis. 
Based on these findings,  we conclude that RMA/S cells are 
able to process and present endogenously synthesized N pro- 
tein  to CTL in association  with  K b. 
Characteristics of  RMA/S Presentation of  N.  We performed 
several additional  experiments to characterize the ability of 
RMA/S cells to present N  to CTL. First, we compared the 
amount of input VSV required to sensitize RMA and RMA/S 
cells for CTL recognition.  After infection of cells at mul- 
tiplicities of infection ranging from 0.004 to 2 PFU per cell, 
RMA and RMA/S cells demonstrated only minor differences 
in presentation of VSV antigens over the entire range tested 
(Fig. 1 A). Immunoperoxidase staining of the same cells used 
in the CTL assay indicated that RMA/S cells expressed similar 
quantities  of N  protein at a  given multiplicity of infection 
(not  shown). 
We next examined the time required by RMA and RMA/S 
cells to present N  to CTL.  This was done by adding BFA 
to cells at various times after infection with VSV, and main- 
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Figure 1.  Characteristics of RMA/S processing  of VSV N  protein. 
Anti-N CTL generated by VSV in vitro stimulation of splenocyte-derived 
N-Vac-primed mice were used to characterize  the antigen processing ca- 
l~..dty ofRMA (O) or RMA/S (11) cells. E/T ratios were 20:1 (A), 10:1 
(/3), and 15:1 (C and D). Percent of cytotoxicity of uninfected cells was 
subtracted from all values. (A) Amount of virus required for sensitization. 
Cell were infected with various PFU of VSV per cell, incubated for 2 h 
and tested in a 4-h cytotoxicity  assay. (B) Tune course of antigen presenta- 
tion. Cells were infected for 2 h and tested in a 4-h cytotoxicity  assay (6-h 
point in graph). The other points on the graph represent the times at 
which BFA was added to cells to block additional antigen processing, (C) 
Time of protein synthesis required for antigen presentation. Cells were 
infected for 2.5 h and tested in a 4-h cytotoxicity assay (6.5-h point in 
graph). The other points on the graph represent the times at which cyclo- 
heximide was added to cells to block additional synthesis of N protein. 
(D) Time of presentation required after blocking protein synthesis. RMA 
and RMA/S cells treated with cycloheximide  after 45 rain of infection 
in C, were treated with BFA after various  times of additional incuba- 
tion, and tested in a 4-h microcytotoxicity  assay beginning 2.5 h after in- 
fection. This assay measures the rate of antigen presentation from a pool 
of N  protein synthesized before  the addition of cycloheximide. 
raining BFA throughout the remaining incubations. As seen 
in Fig. 1 B, while RMA cells were sensitized for 50%  of 
their maximal lysis by ~105  min, RMA/S cells required 
nearly twice as long to achieve a similar level of recognition. 
This difference could be due to: (a) a requirement for higher 
levels of protein, or (b) slower formation or transport of K b- 
peptide complexes. To help distinguish between these mech- 
anisms, we stopped the synthesis of VSV proteins by adding 
protein synthesis inhibitors to cells at various times after in- 
fection. Whereas RMA cells expressed sufficient N after 45 
min of virus infection to sensitize cells at maximal levels, 
RMA/S cells required infection for at least an additional 210 
min to achieve similar levels of sensitization, which indicates 
that greater amounts of N are required to load sufficient class 
I molecules for target cell sensitization (Fig. 1 C). In the same 
experiment, we examined the kinetics of presentation of a 
pool of N produced before the addition of cycloheximide by 
treating cells with BFA at various times after blocking pro- 
tein synthesis 45 rain post-infection. While RMA cells trans- 
ported sufficient Kb-peptide  complexes to reach  half-max- 
imal lysis within 45 rain after adding cycloheximide, RMA/S 
cells required approximately twice as much time to achieve 
the same relative level of recognition (Fig. 1 D). This indi- 
cates that the formation or transport of class I-peptide com- 
plexes occurs more slowly in the mutants. 
In additional experiments (not shown), we found that at 
least a 32-fold higher concentration of an anti-CD8 mAb 
(3.168 [12]) was required to block lysis of VSV-infected RMA 
cells compared with RMA/S cells by N-specific CTL when 
this antibody was included during the cytotoxicity assay. The 
specificity of inhibition was demonstrated by comparison to 
the low levels of inhibition obtained using an antibody specific 
for CD4. 
These experiments indicate that while RMA/S cells are 
capable of processing N  and presenting it to CTL, this re- 
quires more N  protein, occurs more slowly than presenta- 
tion by RMA cells, and has a greater dependence on CDS-class 
I interactions. 
After Prolonged PR8 Infection, RMA/S  Cells Present En- 
dogenously S~thesized NP.  Our finding that RMA/S cells 
were capable of presenting VSV N  protein given sufficient 
levels of N and long enough time to process and present it 
suggested that the cells might be able to prevent influenza 
virus NP given a sufficiently long infection period before in- 
cubation with CTL. In their studies with RMA/S cells, Town- 
send et al. (1) infected cells for 1.5 h before their incubation 
with CTL in a 4-h assay. Under these conditions, we also 
found that PKS-infected RMA/S cells were not lysed by NP- 
specific CTL populations induced by priming mice with PR8 
and restimulating splenocytes in vitro with NP~s-3s0 (Table 
1). If, however, cells were infected for at least an additional 
90 min before the assay, they were lysed at low but consis- 
tent levels by NP-specific CTL (Table 1). The specificity of 
recognition is shown by the reciprocal nature of recognition 
by NP- and VSV-specific  CTL of PR.8- and VSV-infected cells, 
respectively. Presentation of NP was blocked by BFA and also 
by protein synthesis inhibitors (not shown). Thus, as with N, 
RMA/S cells are able to process NP from a biosynthesized 
cytosolic pool of antigen and present it to CTL via the stan- 
dard endogenous pathway. 
Discussion 
In contrast to prior reports, we find that the antigen pro- 
cessing deficit in RMA/S cells is partial rather than absolute 
in nature. Thus, RMA/S cells are able to present N  or NP 
to CTL, but they require more antigen and more time to 
either generate the dass I-peptide complex, or transport it 
to the cell surface (or both). The partial nature of the deficit 
could reflect an incomplete deficit in one of the steps of the 
normal class I-restricted pathway,  or a total deficit that is 
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nism  constitutively functioning  at low efficiency. 
The fact that RMA/S cells are capable of processing and 
presenting cytosolic antigens does not necessarily indicate that 
they create normal class I-peptide complexes. Indeed, our data 
are consistent with  the possibility that  the peptide-dass  I 
complexes on the surface of RMA/S cells are not as stable 
as normal complexes, which in a cell-free system are stable 
for many hundreds  of hours  (4).  As the evidence strongly 
favors the idea that  RMA/S cells express normal ot chains 
and 32-microglobulin (13), less stable complexes would have 
to result either from a deficiency in delivering peptides of 
the proper length to class I molecules (since longer or shorter 
peptides bind with a much lower affinity to class I molecules 
[14, 15]), or from a deficiency in a molecule required for class 
I assembly in vivo. That RMA/S cells might produce defec- 
tive dass I-peptide complexes is consistent with thdr increased 
sensitivity to blocking by anti-CD8 antibodies, first observed 
by Ohlen et al. (16) studying alloreactive recognition of RMA 
and RMA/S cells. Via HPLC analysis  of antigenic peptides 
acid extracted from RMA/S ceils (14), it should be possible 
to directly determine the nature of the peptide--class  I com- 
plex in  the cells. 
Antigen processing mutants have attracted wide interest 
for determining  the nature of class I molecules recognized 
by alloreactive CTL.  Based on the recognition of RMA/S 
ceils by ailoreactive CTL clones, Ohlen et al. (16) proposed 
that some alloreactive CTL recognize peptides produced from 
proteins with endoplasmic reticulum insertion sequences. Our 
findings that two cytosolic proteins are presented by RMA/S 
cells indicate that there is no need to invoke this limitation 
to presentation  of allo-determinants.  It has  also been pro- 
posed that a portion of the alloreactive response is directed 
solely to class I molecules, either in a peptide-free state or 
while bound to peptide.  RMA/S cells  and similar antigen 
processing mutants have been used as a means of identifying 
alloreactive clones that recognize "empty" class I molecules. 
Our findings indicafe that RMA/S calls, at least, are not well 
suited for this purpose, as they dearly maintain some capacity 
to process and present proteins  to CTL. 
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